Evidence map›Paper›PMID 29885865›Full record

ArticleEBioMedicine2018

Mesenchymal Stem Cells Control Complement C5 Activation by Factor H in Lupus Nephritis.

Haijun Ma, Chang Liu, Bingyu Shi, Zhuoya Zhang, Ruihai Feng, Minghao Guo, Liwei Lu, Songtao Shi, Xiang Gao, Wanjun Chen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Lipocalin-2 Exacerbates Lupus Nephritis by Promoting Th1 Cell Differentiation.Journal of the American Society of Nephrology : JASN · 2020
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Haijun MaDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China; Department of Rheumatology and Immunology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China.
Chang LiuDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Bingyu ShiDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Zhuoya ZhangDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Ruihai FengDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Minghao GuoDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China.
Liwei LuDepartment of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong, Hong Kong, China.
Songtao ShiDepartment of Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, USA.
Xiang GaoModel Animal Research Center, Nanjing University, Nanjing, China.
Wanjun ChenMucosal Immunology Section, NIDCR, US National Institutes of Health, Bethesda, MD, USA.
Lingyun SunDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. Electronic address: lingyunsun@nju.edu.cn.
Nanjing Drum Tower Hospital · CNFirst Affiliated Hospital of Xinxiang Medical University · CNModel Animal Research Center · CNNational Institute of Dental and Craniofacial Research · USUniversity of Hong Kong · HKUniversity of Pennsylvania · US

Funding

TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and ToleranceZIADE000101 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI CHEN, WANJUN · 2009 to 2025
$36.9M
6 · The paper itself

Abstract

Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE) caused by uncontrolled activation of the complement system. Mesenchymal stem cells (MSCs) exhibit clinical efficacy for severe LN in our previous studies, but the underlying mechanisms of MSCs regulating complement activation remain largely unknown. Here we show that significantly elevated C5a and C5b-9 were found in patients with LN, which were notably correlated with proteinuria and different renal pathological indexes of LN. MSCs suppressed systemic and intrarenal activation of C5, increased the plasma levels of factor H (FH), and ameliorated renal disease in lupus mice. Importantly, MSCs transplantation up-regulated the decreased FH in patients with LN. Mechanistically, interferon-α enhanced the secretion of FH by MSCs. These data demonstrate that MSCs inhibit the activation of pathogenic C5 via up-regulation of FH, which improves our understanding of the immunomodulatory mechanisms of MSCs in the treatment of lupus nephritis.

Indexed as

AdultAnimalsComplement ActivationComplement C5Complement Factor HFemaleHumansInterferon-alphaLupus Erythematosus, SystemicLupus NephritisMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceComplement C5Complement Factor HInterferon-alphaC5FHLupus nephritisMSCs

Identifiers

PMID29885865
PMCPMC6020800
OpenAlexW2807700854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.